Literature DB >> 14971045

Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon.

Weisan Chen1, Kelly-Anne Masterman, Sameh Basta, S M Mansour Haeryfar, Nektaria Dimopoulos, Barbara Knowles, Jack R Bennink, Jonathan W Yewdell.   

Abstract

"Cross-priming" refers to the activation of naive CD8+ T cells by antigen-presenting cells that have acquired nominal antigens from another cell. The biological relevance of cross-priming of CD8+ T cells has recently been challenged (Zinkernagel, R. M., Eur. J. Immunol. 2002. 32: 2385-2392), on the basis that responses are weak or poorly quantitated, and the determinants recognized are undefined. Here we show that cross-priming is a robust process that elicits vigorous primary responses to multiple peptides in two well-defined systems. Our findings support the relevance of cross-priming in CD8+ T cell responses to viruses and tumor cells, and demonstrate that cross-priming elicits CD8+ T cells to determinants generated by the endogenous processing pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14971045     DOI: 10.1002/eji.200324257

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  25 in total

1.  Hematopoietic-specific targeting of influenza A virus reveals replication requirements for induction of antiviral immune responses.

Authors:  Ryan A Langlois; Andrew Varble; Mark A Chua; Adolfo García-Sastre; Benjamin R tenOever
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

2.  Immunogenicity of cytopathic and noncytopathic viral vectors.

Authors:  Gabriela Plesa; Philip M McKenna; Matthias J Schnell; Laurence C Eisenlohr
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 3.  The many sounds of T lymphocyte silence.

Authors:  Ignacio Melero; Ainhoa Arina; Lieping Chen
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 4.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 5.  Designing CD8+ T cell vaccines: it's not rocket science (yet).

Authors:  Jonathan W Yewdell
Journal:  Curr Opin Immunol       Date:  2010-05-04       Impact factor: 7.486

6.  Influenza virus and poly(I:C) inhibit MHC class I-restricted presentation of cell-associated antigens derived from infected dead cells captured by human dendritic cells.

Authors:  Davor Frleta; Chun I Yu; Eynav Klechevsky; Anne-Laure Flamar; Gerard Zurawski; Jacques Banchereau; A Karolina Palucka
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Cross-presentation of a spread-defective MCMV is sufficient to prime the majority of virus-specific CD8+ T cells.

Authors:  Christopher M Snyder; Jane E Allan; Elizabeth L Bonnett; Carmen M Doom; Ann B Hill
Journal:  PLoS One       Date:  2010-03-12       Impact factor: 3.240

8.  Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses.

Authors:  Julia Kim; Vandana Gambhir; Attiya Alatery; Sameh Basta
Journal:  J Biomed Biotechnol       Date:  2010-05-23

Review 9.  Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165

10.  Coxsackievirus B3 inhibits antigen presentation in vivo, exerting a profound and selective effect on the MHC class I pathway.

Authors:  Christopher C Kemball; Stephanie Harkins; Jason K Whitmire; Claudia T Flynn; Ralph Feuer; J Lindsay Whitton
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.